Background: Patients with breast cancer brain metastasis are a heterogeneous group in relation to tumor biology and outcome.
introduction
Breast cancer brain metastasis is becoming a more common finding as a result of the aging of the population, control of systemic disease and the development of imaging techniques [computed tomography (CT) and magnetic resonance imaging (MRI)]. Median survival of patients depends on many factors which are related to the patient, the disease and the method of treatment.
Median survival of patients with untreated brain metastases is only 1 month. Symptomatic treatment with steroids alleviates the clinical symptoms and prolongs survival to 2.5 months. Whole-brain radiotherapy (WBRT) increases median survival to 4 to 6 months. In 10% of patients, surgical excision of brain metastasis, followed by WBRT, prolongs median survival up to 1-2 years. Stereotactic radiosurgery produces similar results [1] . Recently, the role of systemic treatment, used after WBRT (chemotherapy, endocrine therapy and targeted therapy), is under investigation. The effect of systemic treatment, described recently in the literature, may be caused by the increase in permeability of blood-brain barrier after WBRT and by the control of extracranial disease.
Clinical, histopathological and molecular features divide breast cancer into several biological subtypes. Breast cancer with overexpression of human epidermal growth factor receptor 2 (HER2) and triple-negative breast cancer are the most aggressive subtypes, affecting survival [2] .
The first aim of the study was to carry out a comprehensive analysis of 222 consecutive patients with breast cancer and brain metastases, treated in one institution, in order to define the biological subtypes that have a propensity to metastasize to the brain. The second aim was to compare survivals from brain metastases depending on biological subtype and recursive partitioning analysis of Radiation Therapy Oncology Group (RPA RTOG) prognostic class. The third goal of the study was to analyze the efficacy of systemic treatment (chemotherapy, endocrine therapy and targeted therapy) carried out after WBRT in patients with breast cancer and brain metastases. Table 1 . In 96% of patients, brain metastases were detected in MRI and in 4%, they were revealed in CT. In 215 patients (97%), WBRT was carried out, using 4-to 6-MV photon beam by two lateral opposed standard fields covering all intracranial contents. The most common regimen of WBRT was 30 Gy in10 fractions. In 34 patients (15%) with one or two metastatic tumors, metastasectomy followed by WBRT (40 Gy in 20 fractions) was given. In three other patients, stereotactic radiosurgery after WBRT was carried out. After local treatment of brain metastases, systemic treatment was ordered in 160 (72%) patients. The type of systemic treatment is presented in Table 1 .
materials and methods
Of 222 patients, 205 patients were divided into three biological subtypes based on the expression of the estrogen receptor (ER), progesterone receptor (PgR) and HER2. Seventeen patients were excluded from the analysis within biological subgroups because of the lack of possibility to assess the expression of ER/PgR or HER2. Immunohistochemistry (IHC) was carried out for the evaluation of the level of ER, PgR and HER2 expression. FISH analysis for HER2 amplification was carried out in the case of IHC 2+. Patients were divided into three biological subtypes: triple negative (ER2PgR2HER22), HER2 positive (HER2(positive), any ER/ PgR) and luminal (ER/PgR(+) HER2(2)). A comparison of clinical features of patients within three biological subgroups is presented in Table 2 .
Disease-free survival (DFS), overall survival (OS) and survival calculated from brain metastases were analyzed in the entire group, in three RPA RTOG prognostic classes [3] and in three biological subgroups. The role of systemic treatment was analyzed in four biological subgroups: the group of HER2-positive breast cancer patients was additionally divided into HER2(positive)ER/PgR(2) and HER2(positive)ER/PgR(+).
statistical analysis
Descriptive statistics was determined for the patient demographics and clinical characteristics. All tests of hypotheses were conducted at the alpha level of 0.05 with a 95% confidence interval. In order to compare categorical tumor features in the three biological subgroups, the chi-square test was used. For those categorical variables in which the chi-square test was inappropriate because of small numbers, the Fisher's exact test was used. A Cox proportional hazards model was developed to identify factors influencing survival after brain metastasis. The following factors were analyzed: tumornode-metastasis stage at the initial diagnosis, histological type, histological grade, visceral metastases, RPA RTOG prognostic class, biological subtype and systemic treatment after WBRT. Survivals were estimated using the Kaplan-Meier method and compared using the log-rank test. Breast cancers from particular biological subtypes varied depending on the pattern of metastatic spread. In HER2-positive breast cancer patients, metastases in many organs (lung, liver, bones, soft tissue and lymph nodes) were detected. Strong correlation between brain metastases and metastases to the viscera, especially to the lungs, was observed.
In most cases, metastases in the brain were followed by metastases in lungs and liver. In triple-negative breast cancer, brain could be the first site of distant metastasis (26% of patients) or brain metastases could appear subsequently after dissemination to the lungs. In luminal subtype, the bones and lungs, but not the brain, were the most frequent site of metastasis. Locoregional failure was observed in all biological subtypes, but it was the most frequent in HER2-positive breast cancer subtype. To summarize, lung was the most common site of distant metastases preceding the appearance of brain metastases. Triple-negative breast cancer subtype had a special propensity to metastasize to the brain as a sole region of the body.
Furthermore, patients in biological subgroups differed depending on performance status. Triple-negative breast cancer patients were more often in RPA RTOG prognostic class III than patients in HER2-positive and luminal subgroups (51%, 23% and 28%, respectively). Similarly, the rate of patients treated systemically after WBRT differed within biological subgroups and was the lowest in triple-negative breast cancer patients (60%). The characteristics in biological subgroups are presented in Table 2 .
survivals in the entire group, within biological subgroups and within RPA RTOG prognostic classes
In the entire group, median DFS and OS was 1.66 and 4.27 years, respectively. Median DFS in three biological subgroups did not differ significantly (P = 0.78). Median OS in subgroup of triple-negative, HER2-positive and luminal breast cancer Median survival calculated from brain metastases in the entire group was 7.5 months and in triple-negative, HER2-positive and luminal subtypes, it was 3.7, 9 and 15 months, respectively (P = 0.015). Median survival calculated from brain metastases in RPA RTOG prognostic classes I, II and III was 15, 11 and 3 months, respectively (P = 0.0000). Survivals in the entire group and biological subgroups are presented in Table 3 , and survivals in RPA RTOG prognostic classes are presented in Table 4 and Figure 1 .
survivals depending on systemic treatment after WBRT
Median survival from brain metastases in patients without and with systemic treatment after WBRT was 3 and 10 months, respectively (P = 0.0001). In the subgroup of luminal breast cancer, median survival without and with systemic therapy was 3 and 14 months, respectively (P = 0.006). In the group of HER2(positive)ER/PgR(+), median survival without further treatment, after chemotherapy and after chemotherapy with trastuzumab was 2, 8 and 13 months, respectively (P = 0.000).
In the group of HER2(positive)ER/PgR(2), median survival without further treatment, after chemotherapy and after chemotherapy with trastuzumab was 4, 8 and 10 months, respectively (P = 0.004). In triple-negative breast cancer patients, median survival without and with chemotherapy was 3 and 4 months, respectively (P = 0.21). The results are presented in Table 5 and in Figure 2 .
factors influencing survival after WBRT-multivariate analysis
The Cox multivariate analysis revealed that the most important factors influencing survival from brain metastasis were RPA RTOG prognostic class, visceral metastasis and the use of systemic treatment after WBRT. Patients in RPA RTOG prognostic class III and patients with metastases to the viscera were at a higher risk of death than patients in prognostic class I and II and patients without visceral metastases. Contrary, patients in whom systemic therapy was ordered after WBRT were at a lower risk of death than patients who underwent only WBRT. Biological subtype was not a factor that statistically significantly influenced survival in Cox analysis. The results are presented in Table 6 .
discussion biological subtypes
Breast cancer can be divided into at least three distinct diseases with heterogeneous expression of ER/PgR and HER2 [2, 4] . Luminal-type cancers tend to have the most favorable longterm survival, whereas the basal-like and HER2-positive tumors are most sensitive to chemotherapy but have the worst prognosis [5] . Based on the literature, 12%-16% of all breast cancer patients have triple-negative subtype, 20%-25% have HER2-positive subtype and 65%-70% have luminal subtype of cancer at initial diagnosis [6] . In our material, we analyzed the rates of breast cancer subtypes among patients with detected brain metastases. The proportion of patients with brain metastases in triple-negative, HER2-positive and luminal subtypes was 28%, 53% and 19%, respectively. The result indicates that triple-negative and HER2-positive breast cancer have a special predisposition to metastasize to the brain. In both the mentioned subgroups of patients, the ratio of the patients with brain metastasis to the patients in whole subgroup was 2 : 1. Contrary to these two subgroups, in patients with luminal breast cancer, the ratio of the patients with brain metastasis to those in the whole subgroup of luminal subtype was 1 : 3. These data are in agreement with the observation of other authors [7] [8] [9] and indicate that HER2-positive and triple-negative breast cancers are more likely to metastasize to the brain and that the propensity of luminal breast cancer for brain metastases is low.
Our observations also indicate that in triple-negative breast cancer, there is a specific biology that drives a tumor to metastasize preferentially to the lungs or directly to the brain. In HER2-positive breast cancer, the likelihood of brain metastases is rather the consequence of a general metastatic potential, especially to the viscera (lungs and liver). These observations correspond to other studies [10] [11] [12] . Summary of the clinical features and prognosis of particular biological subtypes of breast cancer is presented in Table 7 .
survival after the diagnosis of brain metastases
In the present study, the median survival from brain metastases was 7.5 months and it is comparable with or even better than in other published data [11, 12] . original article
Annals of Oncology
The affiliation to the RPA RTOG prognostic class indicated by Gaspar et al. [3] seems to be the strongest prognostic factor influencing survival from brain metastasis. In the present study, a strong correlation between RPA RTOG prognostic class and survival from brain metastasis was detected. Patients in RPA RTOG prognostic class III had the worst prognosis and the risk of death in this group was 3.4 times higher than in the others. Similar observation was done in our previous study, examining the group of patients with single brain metastasis, treated with neurosurgery and WBRT [13] .
the role of systemic treatment after WBRT-differences depending on biological subtype For many years, chemotherapy and endocrine therapy have not been considered to play a role in the treatment of patients with brain metastases because of the presence of the blood-brain barrier. Recently, the role of systemic treatment after WBRT is under investigation. The studies have proved the permeability of blood-brain barrier in patients with brain metastases and in patients after WBRT. It was also observed that systemic therapy carried out after WBRT prolonged survival due to the control of extracranial disease. Actually, after WBRT of brain metastases, the blood-brain barrier is, in part, disrupted so that many chemotherapeutics and hormonal agents may reach a therapeutic level in tumors.
In the literature, the objective response rate after chemotherapy regimens combining cyclophosphamide, 5-fluorouracil, methotrexate and epirubicin was achieved in 50%-59% patients, and median survival time was 7 months [14] . The response rate after cisplatin and etoposide was 38%-55% and median time of the response was 8-13 months [15] . High dose of methotrexate was active in recurrent brain metastasis; however, the risk of leucoencephalopathy was a limiting factor [16] . Capecitabine seems to be also an attractive drug [17] . Temozolomide has shown no activity as a single agent or in combination with vinorelbine for breast cancer brain metastases [18] . Endocrine drugs, tamoxifen and letrozole, can cross the blood-brain barrier and seem to be effective in brain metastases [19, 20] .
Targeted therapies such as trastuzumab and lapatinib have been increasingly investigated in patients with breast cancer brain metastases, in recent years. The studies confirmed that trastuzumab prolonged survival from brain metastases in patients with HER2-positive breast cancer [9, [21] [22] [23] . Lapatinib is the second targeted drug investigated in breast cancer brain metastases, but modest activity of this drug was assessed [24] .
In the present study, the benefit of systemic treatment after WBRT was detected. The results of the study confirmed the opinion that systemic treatment should be continued in at least three of the four biological subgroups. conclusions 1 Patients with breast cancer brain metastasis are a heterogeneous group that differs in relation to tumor biology and prognosis. HER2-positive and triple-negative breast cancers are more likely to metastasize to the brain. The propensity of luminal breast cancer for metastases to the brain is low. Triple-negative breast cancer is the most aggressive and refractory disease. 2 RPA RTOG prognostic class, the occurrence of visceral metastasis and the use of systemic treatment after WBRT are the most important factors influencing survival after WBRT. 3 Chemotherapy, endocrine therapy and targeted therapy prolong survival from brain metastases in luminal and HER2-positive breast cancer patients and should be continued after WBRT. In the group of HER2-positive breast cancer patients, trastuzumab added to chemotherapy had additional, positive impact on survival due to control of extracranial disease. Lack of benefit of chemotherapy, observed in triple-negative breast cancer patients, seems to be the consequence of poor performance status in half of the group and no response to chemotherapy in rest of the patients. WBRT, whole-brain radiotherapy. 
